摘要
目的探讨彩色多普勒超声联合血清糖类蛋白125、糖类蛋白724检测对卵巢良恶性肿瘤的诊断价值.方法将经病理学检查明确诊断的77例卵巢恶性肿瘤患者设为恶性组,120例卵巢良性肿瘤设为良性组.比较两组经阴道彩色超声检查的Finkler超声评分、卵巢间质动脉阻力指数及血清糖类蛋白125、糖类蛋白724水平;以病理诊断作为判断标准,分析超声联合血清糖类蛋白125、糖类蛋白724检测对卵巢良恶性肿瘤的灵敏度及特异度.结果恶性组患者Finkler超声评分显著高于良性组(P<0.01),卵巢间质动脉阻力指数值显著低于良性组(P<0.01).超声联合血清糖类蛋白125、糖类蛋白724检测对卵巢恶性及良性肿瘤患者诊断的灵敏度(97.4%)、特异度(90.0%)显著高于超声(87.0%、84.2%)、血清糖类蛋白125(42.9%、79.2%)、糖类蛋白724(46.8%、75.8%)单一检测(P<0.05或0.01).结论彩色多普勒超声联合血清糖类蛋白125、糖类蛋白724检测能显著提高对卵巢良恶性肿瘤诊断的灵敏度、特异度及诊断水平.
Objective To investigate the diagnostic value of color Doppler ultrasound combined with serum CA125 and CA724 detection for benign and malignant ovarian tumors.Methods 77 cases of ovarian ma-lignant tumors(malignant group)and 120 cases of benign ovarian tumors(benign group)were diagnosed by pathological examination in our hospital.Compare the Finkler ultrasound score,ovarian interstitial ar-tery resistance index and serum CA125 and CA724 levels of two groups through transvaginal color ultra-sound examination.Using pathological diagnosis as the criterion,the sensitivity and specificity of ultra-sound combined with serum CA125 and CA724 for benign and malignant ovarian tumors were analyzed.Results The Finkler score of the malignant group was higher than that of the benign group(P<0.01),and the RI value of the ovarian interstitial artery was lower than that of the benign group(P<0.01).The sensitivity(97.4%)and specificity(90.0%)of ultrasound combined with serum CA125 and CA724 detec-tion in patients with malignant and benign ovarian tumors were significantly higher than those of ultra-sound(87.0%,84.2%),serum CA125(42.9%,79.2%),CA724(46.8%,75.8%)single detection(P<0.05 or 0.01).Conclusions Color Doppler ultrasound combined with serum CA125 and CA724 de-tection can significantly improve the sensitivity,specificity and diagnostic level of ovarian benign and ma-lignant tumors.
作者
张娜
汪玲
刘杰
Zhang Na;Wang Ling;Liu Jie(Zhumadian City Central Hospital,Zhumadian 463000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2020年第5期92-95,共4页
Journal of Clinical Psychosomatic Diseases
基金
河南省医学科技攻关计划项目(编号2018062231)。
